信必可都保治疗轻中度哮喘临床疗效观察

目的评价信必可都保在治疗轻、中度支气管哮喘的临床疗效及安全性。方法对我院30例临床诊断哮喘的轻中度患者应用信必可都保吸入治疗,治疗后4、12周测定第1秒用力呼气容量（FEV1）、FEV1占预计值的百分比（FEV1%）、呼气50%用力肺活量时的流速（FEF50%）和峰值流速（PEF）,观察临床疗效,进行治疗前后对比研究。结果30例中临床控制25例（83.3%）,显效3例（10%）,好转2例（6.7%）。治疗后4周、12周患者哮喘症状较治疗前明显改善（P〈0.05）。治疗后4周、12周患者肺功能监测指标FEV1、FEV1%、FEF50%、PEF较治疗前明显增加（P〈0.05）;但治疗后4周与治疗后12周之间无统计学差异。结论信必可都保吸入治疗轻中度哮喘起效迅速、疗效确切、安全、副作用小、患者依从性好,值得临床推广应用。

Effects of symbicort turbuhaler in mild and moderate patients with bronchial asthma

Objective To investigate the efficacy and safety of symbicort turbuhaler in the treatment of mild and moderate patients with bronchial asthma.Methods 30 cases treated by inhalation of symbicort turbuhaler,FEV1、FEV1%、FEF50%、PEF were detected 4 weeks and 12 weeks after treatment.The clinical efficacy was observed.Results In 30 cases,25 cases（83.3%）were clinically controlled,3 cases（10%）had effective treatment,2 cases（6.7%）had improvement.The symptoms of asthma improved and FEV1、FEV1%、FEF50%、PEF increased significantly after 4 weeks and 12 weeks treatment compared with：before treatment.There was no significant difference between 4 weeks and 12 weeks after treatment.Conclusions It was quick and safe.Little side-effect was observed using inhalation symbicort turbuhaler in treating mild and moderate patients with bronchial asthma.Patients show good compliances.It is worthy of being applied more in clinical practice.